Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients

被引：17

作者：

Fernandez-Diaz, Carlos ^{[1
]}

Atienza-Mateo, Belen ^{[1
]}

Castaneda, Santos ^{[2
]}

Melero-Gonzalez, Rafael B. ^{[3
]}

Ortiz-SanJuan, Francisco ^{[4
]}

Loricera, Javier ^{[1
]}

Casafont-Sole, Ivette ^{[5
]}

Rodriguez-Garcia, Sebastian ^{[6
]}

Aguilera-Cros, Clara ^{[7
]}

Villa-Blanco, Ignacio ^{[8
]}

Raya-Alvarez, Enrique ^{[9
]}

Ojeda-Garcia, Clara ^{[10
]}

Bonilla, Gema ^{[11
]}

Lopez-Robles, Alejandra ^{[12
]}

Arboleya, Luis ^{[13
]}

Narvaez, Javier ^{[14
]}

Cervantes, Evelin ^{[15
]}

Maiz, Olga ^{[16
]}

Alvarez-Rivas, Maria N. ^{[17
]}

Cabezas, Ivan ^{[18
]}

Salgado, Eva ^{[19
]}

Hidalgo-Calleja, Cristina ^{[20
]}

Fernandez, Sabela ^{[21
]}

Fernandez, Jesus C. ^{[22
]}

Ferraz-Amaro, Ivan ^{[23
]}

Gonzalez-Gay, Miguel A. ^{[1
]}

Blanco, Ricardo ^{[1
]}

机构：

[1] Univ Cantabria, Rheumatol, HU Marques de Valdecilla, IDIVAL, Santander, Spain

[2] UAM, Rheumatol, HU La Princesa, IIS Princesa,Catedra UAM Roche EPID Future, Madrid, Spain

[3] CHU Vigo, Rheumatol, Vigo, Spain

[4] HU La Fe, Rheumatol, Valencia, Spain

[5] HU Germans Trias & Pujol, Rheumatol, Madrid, Spain

[6] HU Clin, Rheumatol, Barcelona, Spain

[7] HU Virgen del Rocio, Rheumatol, Seville, Spain

[8] H Torrelavega, Rheumatol, Cantabria, Spain

[9] HU San Cecilio, Rheumatol, Granada, Spain

[10] HU Virgen Macarena, Rheumatol, Seville, Spain

[11] HU La Paz, Rheumatol, Madrid, Spain

[12] HU Leon, Rheumatol, Leon, Spain

[13] HU Cent Asturias, Rheumatol, Asturias, Spain

[14] HU Bellvitge, Rheumatol, Barcelona, Spain

[15] HU Santiago, Rheumatol, Santiago De Compostela, A Coruna, Spain

[16] HU Donostia, Rheumatol, Donosti, Spain

[17] HU Luca Augusti, Rheumatol, Lugo, Spain

[18] HU Rio Hortega, Rheumatol, Valladolid, Spain

[19] CHU Ourense, Rheumatol, Orense, Spain

[20] HU Salamanca, Rheumatol, Salamanca, Spain

[21] HU Cabuenes, Rheumatol, Asturias, Spain

[22] CHU A Coruna, Rheumatol, La Coruna, Spain

[23] HU Canarias, Rheumatol, Tenerife, Spain

来源：

RHEUMATOLOGY | 2022年 / 61卷 / 01期

关键词：

rheumatoid arthritis; interstitial lung disease; abatacept; methotrexate; conventional disease-modifying antirheumatic drugs; high-resolution computed tomography; comorbidity; METHOTREXATE; MORTALITY; CLASSIFICATION; PNEUMONITIS; CRITERIA; RISK; DRUG;

D O I：

10.1093/rheumatology/keab317

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective To assess the efficacy and safety of abatacept (ABA) in monotherapy (ABA(MONO)) vs combined ABA [ABA plus MTX (ABA(MTX)) or ABA plus non-MTX conventional synthetic DMARDs (csDMARDs) (ABA(NON-MTX))] in RA patients with interstitial lung disease (ILD) (RA-ILD). Methods This was a restrospective multicentre study of RA-ILD Caucasian patients treated with ABA. We analysed in the three groups (ABA(MONO), ABA(MTX), ABA(NON-MTX)) the following outcome variables: (i) dyspnoea; (ii) forced vital capacity (FVC) and diffusion capacity of the lung for the carbon monoxide (DLCO); (iii) chest high-resolution CT (HRCT); (iv) DAS28-ESR; (v) CS-sparing effect; and (vi) ABA retention and side-effects. Differences between basal and final follow-up were evaluated. Multivariable linear regression was used to assess the differences between the three groups. Results We studied 263 RA-ILD patients (mean +/- s.d. age 64.6 +/- 10 years) [ABA(MONO) (n = 111), ABA(MTX) (n = 46) and ABA(NON-MTX) (n = 106)]. At baseline, ABA(MONO) patients were older (67 +/- 10 years) and took higher prednisone dose [10 (interquartile range 5-15) mg/day]. At that time, there were no statistically significant differences in sex, seropositivity, ILD patterns, FVC and DLCO, or disease duration. Following treatment, in all groups, most patients experienced stabilization or improvement in FVC, DLCO, dyspnoea and chest HRCT as well as improvement in DAS28-ESR. A statistically significant difference between basal and final follow-up was only found in CS-sparing effect in the group on combined ABA (ABA(MTX) or ABA(NON-MTX)). However, in the multivariable analysis, there were no differences in any outcome variables between the three groups. Conclusion In Caucasian individuals with RA-ILD, ABA in monotherapy or combined with MTX or with other conventional-DMARDs seems to be equally effective and safe. However, a CS-sparing effect is only observed with combined ABA.

引用

页码：299 / 308

页数：10

共 43 条

[1] Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
[2] [Anonymous], 2002, Am J Respir Crit Care Med, V165, P277304, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]
[3] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
ARNETT, FC
EDWORTHY, SM
BLOCH, DA
MCSHANE, DJ
FRIES, JF
COOPER, NS
HEALEY, LA
KAPLAN, SR
LIANG, MH
LUTHRA, HS
MEDSGER, TA
MITCHELL, DM
NEUSTADT, DH
PINALS, RS
SCHALLER, JG
SHARP, JT
WILDER, RL
HUNDER, GG
[J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
[4] Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis
Atzeni, Fabiola
Boiardi, Luigi
Salli, Salvatore
Benucci, Maurizio
Sarzi-Puttini, Piercarlo
[J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (07) : 649 - 657
[5] METHOTREXATE-RELATED PULMONARY COMPLICATIONS IN RHEUMATOID-ARTHRITIS
BARRERA, P
LAAN, RFJM
VANRIEL, PLCM
DEKHUIJZEN, PNR
BOERBOOMS, AMT
VANDEPUTTE, LBA
[J]. ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (07) : 434 - 439
[6] T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis
Boleto, Goncalo
Guignabert, Christophe
Pezet, Sonia
Cauvet, Anne
Sadoine, Jeremy
Tu, Ly
Nicco, Carole
Gobeaux, Camille
Batteux, Frederic
Allanore, Yannick
Avouac, Jerome
[J]. ARTHRITIS RESEARCH & THERAPY, 2018, 20
[7] Incidence and Mortality of Interstitial Lung Disease in Rheumatoid Arthritis
Bongartz, Tim
Nannini, Carlotta
Medina-Velasquez, Yimy F.
Achenbach, Sara J.
Crowson, Cynthia S.
Ryu, Jay H.
Vassallo, Robert
Gabriel, Sherine E.
Matteson, Eric L.
[J]. ARTHRITIS AND RHEUMATISM, 2010, 62 (06): : 1583 - 1591
[8] Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study
Cassone, Giulia
Manfredi, Andreina
Atzeni, Fabiola
Venerito, Vincenzo
Vacchi, Caterina
Picerno, Valentina
Furini, Federica
Erre, Gian Luca
Tomietto, Paola
Fedele, Anna Laura
Della Casa, Giovanni
Nucera, Valeria
Giannitti, Chiara
Salvarani, Carlo
Sebastiani, Marco
[J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)
[9] Conway R, 2014, ARTHRITIS RHEUMATOL, V66, P803, DOI [10.1002/art.38322, 10.1002/art.38732]
[10] Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor a agents, a retrospective cohort study
Curtis, Jeffrey R.
Sarsour, Khaled
Napalkov, Pavel
Costa, Laurie A.
Schulman, Kathy L.
[J]. ARTHRITIS RESEARCH & THERAPY, 2015, 17

← 1 2 3 4 5 →